×
About 198 results

ALLMedicine™ Recurrent Bladder Cancer Center

Research & Reviews  59 results

Piperlongumine increases the sensitivity of bladder cancer to cisplatin by mitochondria...
https://doi.org/10.1002/jcla.24452
Journal of Clinical Laboratory Analysis; Pan X, Chen G et. al.

Apr 26th, 2022 - The development of cisplatin resistance often results in cisplatin inefficacy in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established. Gene expression was measured by...

Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-indu...
https://doi.org/10.1016/j.canlet.2022.215615
Cancer Letters; Yan R, Dai W et. al.

Mar 13th, 2022 - Abnormal RNA methylation and dysregulation of miRNA are frequently occurred in bladder cancer. Melittin is a potential drug candidate for intravesical chemotherapy against bladder cancer. However, the underlying epigenetic mechanism by which melit...

Surveillance for Recurrent Bladder Cancer
https://emedicine.medscape.com/article/458825-print

Feb 9th, 2022 - Most cases of noninvasive bladder cancer remain clinically indolent with even a modicum of urologic intervention. Some cases progress, however, and most patients experience recurrence at least once in the follow-up period, creating the need for ac...

Surveillance for Recurrent Bladder Cancer
http://emedicine.medscape.com/article/458825-overview

Feb 9th, 2022 - Practice Essentials Most cases of noninvasive bladder cancer remain clinically indolent with even a modicum of urologic intervention. Some cases progress, however, and most patients experience recurrence at least once in the follow-up period, crea...

Surveillance for Recurrent Bladder Cancer
https://emedicine.medscape.com/article/458825-overview

Feb 9th, 2022 - Practice Essentials Most cases of noninvasive bladder cancer remain clinically indolent with even a modicum of urologic intervention. Some cases progress, however, and most patients experience recurrence at least once in the follow-up period, crea...

see more →

Clinicaltrials.gov  14 results

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT03801278

Dec 13th, 2021 - This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protoco...

Treatment of Recurrent Bladder Cancer With Dendritic Cells
https://clinicaltrials.gov/ct2/show/NCT04184232

Jan 22nd, 2021 - Treatment of recurrent bladder cancer with dendritic cells

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00445601

Jan 18th, 2020 - OBJECTIVES: Primary Compare the efficacy of a single intravesical instillation of gemcitabine hydrochloride vs placebo immediately after transurethral resection of the bladder tumor (TURBT) in preventing recurrence at 2 years in patients with grad...

Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
https://clinicaltrials.gov/ct2/show/NCT03715660

Nov 21st, 2019 - The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently used at the site for...

To Detect the Sensitivity of the UroMark Assay
https://clinicaltrials.gov/ct2/show/NCT02781428

Oct 9th, 2019 - This study is an observational study and participants will receive the standard of care according to local MDT guidelines for the treatment and surveillance of bladder cancer. As the study involves collection of a urine sample, subjects are permit...

see more →

News  6 results

LiPax Elicits Encouraging RFS Rate in Non–Muscle Invasive Bladder Cancer
https://www.onclive.com/view/lipax-elicits-encouraging-rfs-rate-in-non-muscle-invasive-bladder-cancer

Mar 1st, 2022 - LiPax (TSD-001), a precision-targeted, locally-delivered taxane, was found to induce a recurrence-free survival (RFS) rate of 83% in patients with non–muscle invasive bladder cancer (NMIBC) who had undergone transurethral resection of bladder tumo...

Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer
https://www.onclive.com/view/yale-cancer-center-study-shows-novel-test-can-detect-new-and-recurrent-bladder-cancer

Jun 11th, 2021 - A revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine, according to a study led by researchers at Yale Cance...

Persistent BCG Shortages Lead to Hard Choices in Bladder Cancer
https://www.onclive.com/view/persistent-bcg-shortages-lead-to-hard-choices-in-bladder-cancer

Dec 5th, 2020 - Edward Messing, MD Over the years, the Tice strain of bacillus Calmette—Guérin (BCG) has emerged as a go-to drug for treating primary and recurrent bladder cancer, but in the United States and some other countries, a constellation of marketplace ...

Active Surveillance OK For Non-Muscle Invasive Bladder Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/70930

Feb 3rd, 2018 - Action Points Note that this observational study suggests that, for certain individuals with low-grade recurrent bladder cancer, active surveillance may be a viable alternative to transurethral resection of bladder tumor. The study did not take in...

A New Epilepsy Etiology
https://www.medscape.com/viewarticle/777407_1

Jan 15th, 2013 - Introduction Autoimmune epilepsy is a newly recognized treatable cause of uncontrolled seizures. A retrospective review of patients who presented with uncontrolled seizures to both the epilepsy and neuroimmunology clinics of the Mayo Clinic betwee...

see more →